Skip to main content

Breast Cancer

Breast Cancer

Comparison of Healthcare Resource Utilization and Costs in Women with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer Treated with CDK4/6 Inhibitors

Breast Cancer

Incidence of Thrombotic Events with CDK4/6 Inhibitor Use in Real-World Practice Compared with Clinical Trial Settings

Breast Cancer

Assessment of Characteristics, Utilization Patterns, and Outcomes in the Real-World Setting of Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer Treated with Abemaciclib

Breast Cancer

Capecitabine or Endocrine Therapy as Maintenance Therapy for Hormone Receptor–Positive, HER2-Negative Breast Cancer

Breast Cancer

Real-World Data of Palbociclib and Endocrine Therapy in Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

Breast Cancer

Impact of the COVID-19 Pandemic in the United States on First-Line Treatment Trends in Metastatic Breast Cancer

Breast Cancer

Updated Results from the Phase 3b CompLEEment-1 Study of Ribociclib plus Letrozole in the Treatment of Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

Breast Cancer

For Patients with PIK3CA Mutation–Positive Advanced Breast Cancer, Treatment with Alpelisib plus Fulvestrant May Be Beneficial

Breast Cancer

Perspectives on Balancing Toxicity and Efficacy When Managing Advanced HER2-Negative Breast Cancer with First-Line Treatment

Breast Cancer

Efficacy Study of Everolimus and Exemestane for the Treatment of Patients with Metastatic Hormone Receptor–Positive Breast Cancer Previously Treated with CDK4/6 Inhibitors

3
4
5
6
7
8
9

Page 6 of 11
Results 51 - 60 of 101